Treatment of Salas-ul-Baul (Stress Urinary Incontinence) with Unani medicine Kundri

An open-label, Multicentric Clinical Validation Study to Evaluate the Efficacy and Safety of Unani Pharmacopoeial formulation â?? Kundri in Salas-ul-Baul (Stress Urinary Incontinence)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/06/034371

Enrollment

220

Registered

2021-06-24

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N393- Stress incontinence (female) (male)

Interventions

Intervention1: Kundri: 6gm twice daily to be taken orally with water for twelve weeks Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects of either sex between the age group of 40 to 70 years 2. Involuntarily dribbling of urine (Even small drops) 3. Involuntary leakage of urine triggered by coughing, sneezing, laughing, bending, lifting or exercising

Exclusion criteria

Exclusion criteria: 1. Pregnant women. 2. Obese/Fatty abdomen. 3. Prolapsed disc and dislocated vertebrae. 4. Subjects with Renal/Urinary Bladder Calculi 5. Known cases of Diabetes Mellitus, Parkinsonâ??s and multiple sclerosis 6. Other systemic illness requiring long term treatment.

Design outcomes

Primary

Measure	Time frame
Improvement in signs and symptoms of Salas-ul-Baul (Stress Urinary Incontinence)Timepoint: The patient will be assessed at every 2 weeks. The total duration is 12weeks	—

Secondary

Measure	Time frame
Haematological and biochemical assessment for safety assessment Timepoint: At every 2 weeks till 12 weeks	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@rediffmail.com9213511298

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026